FDA Cancels Levothyroxine Product Stability Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency says it does not plan to re-advertise for bids in the near term.
You may also be interested in...
FDA Solicits Bids For Levothyroxine Stability Testing
Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.